Skip to main content

Table 1 Patient characteristics

From: Effects of Tocilizumab in COVID-19 patients: a cohort study

  All (N = 60) Died (n = 9)
Age, median (range), years 54 (26–87) 58 (33–84)
Male, n (%) 40 (66.7) 8 (88.9)
Ethnicity
 Hispanic 38 (63.3) 6 (66.7)
 Black 14 (23.3) 2 (22.2)
 White 7 (11.7) 1 (11.1)
 Asian 1 (1.7) 0 (0.0)
Comorbidities
 Obese (BMI > 30) 35 (58.3) 6 (66.7)
 Hypertension 32 (53.3) 8 (88.9)
 Diabetes 15 (25.0) 3 (33.3)
 Congestive heart failure 4 (6.7) 1 (11.1)
 Coronary artery disease 1 (1.7) 0 (0.0)
 Asthma 4 (6.7) 0 (0.0)
 COPD 1 (1.7) 1 (11.1)
 Obstructive sleep apnea 2 (3.3) 0 (0.0)
 HIV 1 (1.7) 0 (0.0)
 Transplant 1 (1.7) 0 (0.0)
Concomitant therapies
 Hydroxychloroquine 52 (86.7) 8 (88.9)
 Corticosteroids 32 (53.3) 5 (55.6)
 Inhaled nitric oxide 5 (8.3) 1 (11.1)
 Intravenous immunoglobulin (IVIG) 4 (6.6) 0 (0.0)
 Tacrolimus 2 (3.3) 1 (11.1)
 Convalescent plasma 2 (3.3) 0 (0.0)
 Plasmapheresis 1 (1.7) 0 (0.0)
Time from symptom onset to hospital admission, median (range), days 6 (1–14) 7 (1–14)
Time from hospital admission to receiving tocilizumab, median (range), days 2 (0–12) 1 (0–4)
Time from symptom onset to receiving tocilizumab, median (range), days 8 (1–21) 8 (1–15)
  1. Note: abnormal medians highlighted in bold
  2. aLuo H, et al. Clin Lab 2019;65(3).